Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)
Spain · Delayed Price · Currency is EUR 59.00
+0.40 (0.68%)
Aug 7, 2026, 1:45 PM CET
BME:ROVI Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 773.05 | 743.48 | 763.75 | 829.51 | 817.7 | 648.68 | |
Revenue Growth | 3.21% | -2.65% | -7.93% | 1.44% | 26.06% | 54.46% |
Cost of Revenue | 157.43 | 261.46 | 286.05 | 341.09 | 300.94 | 263.86 |
Gross Profit | 615.62 | 482.03 | 477.7 | 488.42 | 516.76 | 384.82 |
Selling, General & Admin | 155.94 | 141.09 | 135.66 | 122.81 | 106.52 | 89.8 |
Depreciation & Amortization Expenses | 33.6 | 30.37 | 28.02 | 24.33 | 22.87 | 21.36 |
Other Operating Expenses | 156.31 | 124.78 | 134.48 | 121.03 | 131.52 | 92.26 |
Total Operating Expenses | 345.86 | 296.24 | 298.15 | 268.17 | 260.91 | 203.43 |
Operating Income | 134.84 | 185.84 | 179.4 | 220.13 | 255.85 | 181.57 |
Interest Income | 1.85 | 1.15 | 0.12 | 1.38 | 3.74 | 0.25 |
Interest Expense | -4.27 | -2.85 | -2.35 | -0.95 | -0.85 | -0.91 |
Other Non-Operating Income (Expense) | -0.47 | -0.82 | 0.38 | -0.28 | 2.83 | 1.89 |
Total Non-Operating Income (Expense) | -2.89 | -2.52 | -1.86 | 0.15 | 5.72 | 1.24 |
Pretax Income | 235.21 | 183.26 | 177.69 | 220.41 | 257.97 | 182.63 |
Provision for Income Taxes | 50.17 | 42.9 | 40.81 | 50.11 | 58.3 | 29.55 |
Net Income | 185.04 | 140.36 | 136.88 | 170.3 | 199.67 | 153.08 |
Minority Interest in Earnings | -0.14 | -0.08 | -0.01 | -0.04 | -0 | - |
Net Income to Common | 185.18 | 140.44 | 136.88 | 170.34 | 199.67 | 153.08 |
Net Income Growth | 40.00% | 2.60% | -19.64% | -14.69% | 30.44% | 150.71% |
Shares Outstanding (Basic) | 51 | 51 | 51 | 53 | 53 | 55 |
Shares Outstanding (Diluted) | 51 | 51 | 51 | 53 | 53 | 55 |
Shares Change | -0.01% | -0.13% | -3.73% | -0.51% | -3.50% | 0.03% |
EPS (Basic) | 3.62 | 2.75 | 2.67 | 3.20 | 3.73 | 2.76 |
EPS (Diluted) | 3.62 | 2.75 | 2.67 | 3.20 | 3.73 | 2.76 |
EPS Growth | 40.02% | 3.00% | -16.56% | -14.21% | 35.14% | 150.91% |
Free Cash Flow | 121.77 | 36.36 | 48.28 | 48.7 | 186.88 | 109.22 |
Free Cash Flow Growth | 326.94% | -24.69% | -0.87% | -73.94% | 71.10% | 1348.77% |
Free Cash Flow Per Share | 2.38 | 0.71 | 0.94 | 0.92 | 3.50 | 1.97 |
Dividends Per Share | 0.959 | 0.959 | 0.935 | 1.104 | 1.294 | 0.956 |
Dividend Growth | 2.60% | 2.60% | -15.28% | -14.69% | 35.39% | 150.68% |
Gross Margin | 79.63% | 64.83% | 62.55% | 58.88% | 63.20% | 59.32% |
Operating Margin | 17.44% | 25.00% | 23.49% | 26.54% | 31.29% | 27.99% |
Profit Margin | 23.94% | 18.88% | 17.92% | 20.53% | 24.42% | 23.60% |
FCF Margin | 15.75% | 4.89% | 6.32% | 5.87% | 22.85% | 16.84% |
EBITDA | 160.28 | 195.44 | 188.81 | 230.36 | 278.72 | 202.94 |
EBITDA Margin | 20.73% | 26.29% | 24.72% | 27.77% | 34.09% | 31.28% |
EBIT | 134.84 | 185.84 | 179.4 | 220.13 | 255.85 | 181.57 |
EBIT Margin | 17.44% | 25.00% | 23.49% | 26.54% | 31.29% | 27.99% |
Effective Tax Rate | 21.33% | 23.41% | 22.97% | 22.73% | 22.60% | 16.18% |